Given the limited efficacy and potential side effects of UCP1 activation in a clinical setting, the possibility of manipulating adipocyte differentiation combined with increasing UCP1-independent thermogenic mechanisms provides potential avenues for therapeutic intervention in key areas of metabolic diseases, including type 2 diabetes and obesity. Here, UCP1 is linked to obesity due to melanocortin 4 receptor deficiency.